Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma

publication date: Jun 30, 2022

Beijing’s BeiGene announced positive results from a global Phase III trial of its PD-1 plus chemotherapy as a therapy for esophageal squamous cell carcinoma (ESCC). Tislelizumab plus chemotherapy increased overall survival to 17.2 months against 10.6 months for chemotherapy alone. The Phase III trial tested tislelizumab as a first-line therapy in patients with advanced or metastatic ESCC. The PD-1 is already approved as a second line ESCC treatment in China. In early 2021, BeiGene out-licensed ex-China rights for the PD-1 to Novartis in a $2.2 billion agreement. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues: